Two  ||| S:0 E:4 ||| CD
novel  ||| S:4 E:10 ||| NN
HSD3B2  ||| S:10 E:17 ||| CD
missense  ||| S:17 E:26 ||| CD
mutations  ||| S:26 E:36 ||| NNS
with  ||| S:36 E:41 ||| IN
diverse  ||| S:41 E:49 ||| JJ
residual  ||| S:49 E:58 ||| JJ
enzymatic  ||| S:58 E:68 ||| JJ
activities  ||| S:68 E:79 ||| NNS
for  ||| S:79 E:83 ||| IN
Δ5-steroids  ||| S:83 E:95 ||| FW
Classical  ||| S:95 E:105 ||| FW
3β-hydroxysteroid  ||| S:105 E:123 ||| FW
dehydrogenase  ||| S:123 E:137 ||| FW
( ||| S:137 E:138 ||| -LRB-
3β-HSD ||| S:138 E:144 ||| NNP
)  ||| S:144 E:146 ||| -RRB-
deficiency  ||| S:146 E:157 ||| NN
( ||| S:157 E:158 ||| -LRB-
3β-HSDD ||| S:158 E:165 ||| NNP
)  ||| S:165 E:167 ||| -RRB-
is  ||| S:167 E:170 ||| VBZ
caused  ||| S:170 E:177 ||| VBN
by  ||| S:177 E:180 ||| IN
loss-of-function  ||| S:180 E:197 ||| JJ
mutations  ||| S:197 E:207 ||| NNS
in  ||| S:207 E:210 ||| IN
the  ||| S:210 E:214 ||| DT
HSD3B2  ||| S:214 E:221 ||| JJ
gene  ||| S:221 E:226 ||| NN
encoding  ||| S:226 E:235 ||| NN
type  ||| S:235 E:240 ||| NN
II  ||| S:240 E:243 ||| NNP
3β-HSD ||| S:243 E:249 ||| NNP
,  ||| S:249 E:251 ||| ,
which  ||| S:251 E:257 ||| WDT
has  ||| S:257 E:261 ||| VBZ
a  ||| S:261 E:263 ||| DT
key  ||| S:263 E:267 ||| JJ
role  ||| S:267 E:272 ||| NN
in  ||| S:272 E:275 ||| IN
steroid  ||| S:275 E:283 ||| JJ
biosynthesis ||| S:283 E:295 ||| NN
,  ||| S:295 E:297 ||| ,
converting  ||| S:297 E:308 ||| VBG
Δ5-steroids  ||| S:308 E:320 ||| CD
to  ||| S:320 E:323 ||| TO
Δ4-steroids  ||| S:323 E:335 ||| CD
in  ||| S:335 E:338 ||| IN
adrenal  ||| S:338 E:346 ||| JJ
glands  ||| S:346 E:353 ||| NN
and  ||| S:353 E:357 ||| CC
gonads ||| S:357 E:363 ||| NN
.  ||| S:363 E:365 ||| .
A  ||| S:365 E:367 ||| DT
patient  ||| S:367 E:375 ||| NN
( ||| S:375 E:376 ||| -LRB-
46 ||| S:376 E:378 ||| CD
,  ||| S:378 E:380 ||| ,
XX ||| S:380 E:382 ||| NNP
)  ||| S:382 E:384 ||| -RRB-
was  ||| S:384 E:388 ||| VBD
found  ||| S:388 E:394 ||| VBN
to  ||| S:394 E:397 ||| TO
have  ||| S:397 E:402 ||| VB
elevated  ||| S:402 E:411 ||| JJ
17-hydroxyprogesterone  ||| S:411 E:434 ||| NNP
( ||| S:434 E:435 ||| -LRB-
17-OHP ||| S:435 E:441 ||| NNP
)  ||| S:441 E:443 ||| -RRB-
[ ||| S:443 E:444 ||| -LRB-
203  ||| S:444 E:448 ||| CD
nmol ||| S:448 E:452 ||| CD
/ ||| S:452 E:453 ||| CD
l  ||| S:453 E:455 ||| NNS
( ||| S:455 E:456 ||| -LRB-
normal  ||| S:456 E:463 ||| JJ
range ||| S:463 E:468 ||| NN
:  ||| S:468 E:470 ||| :
2·94  ||| S:470 E:475 ||| FW
±  ||| S:475 E:477 ||| FW
0·9  ||| S:477 E:481 ||| FW
nmol ||| S:481 E:485 ||| FW
/ ||| S:485 E:486 ||| FW
l ||| S:486 E:487 ||| FW
) ||| S:487 E:488 ||| -RRB-
]  ||| S:488 E:490 ||| -RRB-
by  ||| S:490 E:493 ||| IN
newborn  ||| S:493 E:501 ||| JJ
screening ||| S:501 E:510 ||| NN
.  ||| S:510 E:512 ||| .
Endocrinological  ||| S:512 E:529 ||| JJ
examination  ||| S:529 E:541 ||| NN
revealed  ||| S:541 E:550 ||| VBD
dramatically  ||| S:550 E:563 ||| RB
increased  ||| S:563 E:573 ||| VBD
Δ5-steroids  ||| S:573 E:585 ||| CD
[ ||| S:585 E:586 ||| -LRB-
e.g.  ||| S:586 E:591 ||| FW
17-OH  ||| S:591 E:597 ||| FW
pregnenolone ||| S:597 E:609 ||| FW
:  ||| S:609 E:611 ||| :
910  ||| S:611 E:615 ||| CD
nmol ||| S:615 E:619 ||| CD
/ ||| S:619 E:620 ||| CD
l  ||| S:620 E:622 ||| NNS
( ||| S:622 E:623 ||| -LRB-
normal  ||| S:623 E:630 ||| JJ
range ||| S:630 E:635 ||| NN
:  ||| S:635 E:637 ||| :
12·6  ||| S:637 E:642 ||| FW
±  ||| S:642 E:644 ||| FW
10·5  ||| S:644 E:649 ||| FW
nmol ||| S:649 E:653 ||| FW
/ ||| S:653 E:654 ||| FW
l ||| S:654 E:655 ||| FW
) ||| S:655 E:656 ||| -RRB-
] ||| S:656 E:657 ||| -RRB-
.  ||| S:657 E:659 ||| .
The  ||| S:659 E:663 ||| DT
patient  ||| S:663 E:671 ||| NN
had  ||| S:671 E:675 ||| VBD
virilization  ||| S:675 E:688 ||| VBN
of  ||| S:688 E:691 ||| IN
external  ||| S:691 E:700 ||| JJ
genitalia  ||| S:700 E:710 ||| NN
with  ||| S:710 E:715 ||| IN
labial  ||| S:715 E:722 ||| JJ
fusion ||| S:722 E:728 ||| NN
,  ||| S:728 E:730 ||| ,
suggesting  ||| S:730 E:741 ||| VBG
classical  ||| S:741 E:751 ||| JJ
3β-HSDD ||| S:751 E:758 ||| NN
.  ||| S:758 E:760 ||| .
Consistent  ||| S:760 E:771 ||| JJ
with  ||| S:771 E:776 ||| IN
the  ||| S:776 E:780 ||| DT
endocrinological  ||| S:780 E:797 ||| JJ
data ||| S:797 E:801 ||| NNS
,  ||| S:801 E:803 ||| ,
the  ||| S:803 E:807 ||| DT
patient  ||| S:807 E:815 ||| NN
was  ||| S:815 E:819 ||| VBD
a  ||| S:819 E:821 ||| DT
compound  ||| S:821 E:830 ||| JJ
heterozygote  ||| S:830 E:843 ||| NN
for  ||| S:843 E:847 ||| IN
two  ||| S:847 E:851 ||| CD
novel  ||| S:851 E:857 ||| NN
missense  ||| S:857 E:866 ||| NN
mutations  ||| S:866 E:876 ||| NNS
( ||| S:876 E:877 ||| -LRB-
p.Y190C  ||| S:877 E:885 ||| NNP
and  ||| S:885 E:889 ||| CC
p.S218P ||| S:889 E:896 ||| CD
)  ||| S:896 E:898 ||| -RRB-
that  ||| S:898 E:903 ||| WDT
were  ||| S:903 E:908 ||| VBD
identified  ||| S:908 E:919 ||| VBN
in  ||| S:919 E:922 ||| IN
HSD3B2 ||| S:922 E:928 ||| CD
.  ||| S:928 E:930 ||| .
Both  ||| S:930 E:935 ||| DT
Y190  ||| S:935 E:940 ||| NNP
and  ||| S:940 E:944 ||| CC
S218  ||| S:944 E:949 ||| NNP
are  ||| S:949 E:953 ||| VBP
conserved  ||| S:953 E:963 ||| VBN
among  ||| S:963 E:969 ||| IN
mammals ||| S:969 E:976 ||| NN
.  ||| S:976 E:978 ||| .
The  ||| S:978 E:982 ||| DT
mutant  ||| S:982 E:989 ||| JJ
proteins  ||| S:989 E:998 ||| NNS
had  ||| S:998 E:1002 ||| VBD
severely  ||| S:1002 E:1011 ||| RB
impaired  ||| S:1011 E:1020 ||| VBN
residual  ||| S:1020 E:1029 ||| JJ
enzymatic  ||| S:1029 E:1039 ||| JJ
activity  ||| S:1039 E:1048 ||| NN
in  ||| S:1048 E:1051 ||| IN
vitro ||| S:1051 E:1056 ||| NN
,  ||| S:1056 E:1058 ||| ,
although  ||| S:1058 E:1067 ||| IN
both  ||| S:1067 E:1072 ||| DT
mutants  ||| S:1072 E:1080 ||| NN
retained  ||| S:1080 E:1089 ||| VBD
higher  ||| S:1089 E:1096 ||| JJR
activity  ||| S:1096 E:1105 ||| NN
for  ||| S:1105 E:1109 ||| IN
17-OH  ||| S:1109 E:1115 ||| CD
pregnenolone  ||| S:1115 E:1128 ||| NN
than  ||| S:1128 E:1133 ||| IN
for  ||| S:1133 E:1137 ||| IN
the  ||| S:1137 E:1141 ||| DT
other  ||| S:1141 E:1147 ||| JJ
Δ5-steroids ||| S:1147 E:1158 ||| NN
.  ||| S:1158 E:1160 ||| .
In  ||| S:1160 E:1163 ||| IN
a  ||| S:1163 E:1165 ||| DT
three-dimensional  ||| S:1165 E:1183 ||| JJ
model  ||| S:1183 E:1189 ||| NN
of  ||| S:1189 E:1192 ||| IN
the  ||| S:1192 E:1196 ||| DT
enzyme  ||| S:1196 E:1203 ||| NN
based  ||| S:1203 E:1209 ||| VBN
on  ||| S:1209 E:1212 ||| IN
the  ||| S:1212 E:1216 ||| DT
known  ||| S:1216 E:1222 ||| JJ
structures  ||| S:1222 E:1233 ||| NNS
of  ||| S:1233 E:1236 ||| IN
similar  ||| S:1236 E:1244 ||| JJ
proteins ||| S:1244 E:1252 ||| NNS
,  ||| S:1252 E:1254 ||| ,
both  ||| S:1254 E:1259 ||| DT
mutations  ||| S:1259 E:1269 ||| NN
were  ||| S:1269 E:1274 ||| VBD
located  ||| S:1274 E:1282 ||| VBN
extremely  ||| S:1282 E:1292 ||| RB
close  ||| S:1292 E:1298 ||| VB
to  ||| S:1298 E:1301 ||| TO
the  ||| S:1301 E:1305 ||| DT
predicted  ||| S:1305 E:1315 ||| VBN
substrate-binding  ||| S:1315 E:1333 ||| JJ
pocket ||| S:1333 E:1339 ||| NN
.  ||| S:1339 E:1341 ||| .
This  ||| S:1341 E:1346 ||| DT
suggests  ||| S:1346 E:1355 ||| VBZ
that  ||| S:1355 E:1360 ||| IN
the  ||| S:1360 E:1364 ||| DT
mutations  ||| S:1364 E:1374 ||| NN
can  ||| S:1374 E:1378 ||| MD
cause  ||| S:1378 E:1384 ||| VB
a  ||| S:1384 E:1386 ||| DT
local  ||| S:1386 E:1392 ||| JJ
conformational  ||| S:1392 E:1407 ||| JJ
change  ||| S:1407 E:1414 ||| NN
in  ||| S:1414 E:1417 ||| IN
the  ||| S:1417 E:1421 ||| DT
substrate-binding  ||| S:1421 E:1439 ||| JJ
pocket ||| S:1439 E:1445 ||| NN
,  ||| S:1445 E:1447 ||| ,
leading  ||| S:1447 E:1455 ||| VBG
to  ||| S:1455 E:1458 ||| TO
alterations  ||| S:1458 E:1470 ||| VB
of  ||| S:1470 E:1473 ||| IN
the  ||| S:1473 E:1477 ||| DT
binding  ||| S:1477 E:1485 ||| JJ
affinities  ||| S:1485 E:1496 ||| NNS
for  ||| S:1496 E:1500 ||| IN
Δ5-steroids ||| S:1500 E:1511 ||| CD
.  ||| S:1511 E:1513 ||| .
We  ||| S:1513 E:1516 ||| PRP
identified  ||| S:1516 E:1527 ||| VBD
two  ||| S:1527 E:1531 ||| CD
novel  ||| S:1531 E:1537 ||| NN
missense  ||| S:1537 E:1546 ||| NN
mutations  ||| S:1546 E:1556 ||| NNS
of  ||| S:1556 E:1559 ||| IN
HSD3B2  ||| S:1559 E:1566 ||| NNP
that  ||| S:1566 E:1571 ||| WDT
resulted  ||| S:1571 E:1580 ||| VBD
in  ||| S:1580 E:1583 ||| IN
unbalanced  ||| S:1583 E:1594 ||| JJ
residual  ||| S:1594 E:1603 ||| JJ
enzymatic  ||| S:1603 E:1613 ||| JJ
activities  ||| S:1613 E:1624 ||| NNS
for  ||| S:1624 E:1628 ||| IN
Δ5-steroids ||| S:1628 E:1639 ||| CD
.  ||| S:1639 E:1641 ||| .
As  ||| S:1641 E:1644 ||| IN
a  ||| S:1644 E:1646 ||| DT
potential  ||| S:1646 E:1656 ||| JJ
novel  ||| S:1656 E:1662 ||| NN
mechanism ||| S:1662 E:1671 ||| NN
,  ||| S:1671 E:1673 ||| ,
we  ||| S:1673 E:1676 ||| PRP
propose  ||| S:1676 E:1684 ||| VBP
that  ||| S:1684 E:1689 ||| IN
the  ||| S:1689 E:1693 ||| DT
mutations ||| S:1693 E:1702 ||| NN
,  ||| S:1702 E:1704 ||| ,
which  ||| S:1704 E:1710 ||| WDT
differently  ||| S:1710 E:1722 ||| RB
affect  ||| S:1722 E:1729 ||| VB
the  ||| S:1729 E:1733 ||| DT
activity  ||| S:1733 E:1742 ||| NN
towards  ||| S:1742 E:1750 ||| IN
different  ||| S:1750 E:1760 ||| JJ
substrates ||| S:1760 E:1770 ||| NN
,  ||| S:1770 E:1772 ||| ,
the  ||| S:1772 E:1776 ||| DT
effects  ||| S:1776 E:1784 ||| NNS
of  ||| S:1784 E:1787 ||| IN
these  ||| S:1787 E:1793 ||| DT
mutations  ||| S:1793 E:1803 ||| NNS
provide  ||| S:1803 E:1811 ||| VBP
novel  ||| S:1811 E:1817 ||| JJ
insights  ||| S:1817 E:1826 ||| NNS
into  ||| S:1826 E:1831 ||| IN
the  ||| S:1831 E:1835 ||| DT
pathophysiology  ||| S:1835 E:1851 ||| NN
of  ||| S:1851 E:1854 ||| IN
3β-HSDD ||| S:1854 E:1861 ||| CD
.  ||| S:1861 E:1863 ||| .
